This page is narrower than it looks. It is not about the gut microbiome, which has its own page, and it is not about inflammatory bowel disease, which has another. It is about one specific thing: the intestinal barrier, meaning the single layer of epithelial cells and the junctions between them that decide what gets from the gut lumen into the bloodstream.
That is the thing people mean by leaky gut. The phrase is not a clinical diagnosis and no doctor will write it on a chart, but the underlying physiology is real, measurable, and increased in several diseases. The question worth asking is whether TUDCA does anything to it, and the answer turns out to be unusually well studied in animals and entirely unstudied in humans.
Key Takeaways
- In 72 weaned piglets fed 200 mg/kg TUDCA in their diet for 30 days, diarrhoea incidence fell and intestinal barrier function and immunity improved[1].
- That study identified the mechanism properly rather than by correlation. Knocking down the bile acid receptor TGR5, or inhibiting myosin light chain kinase, abolished TUDCA’s protection of intestinal cells against E. coli[1].
- In a mouse colitis model, 40 percent of vehicle-treated animals died over a 14-day follow-up and every TUDCA-treated animal survived[2]. The earliest measurable effect was prevention of caspase-3 activation in the colon.
- TUDCA also reduced bacterial translocation from gut to spleen, increased mucin production, and blocked the increase in intestinal permeability caused by lipopolysaccharide[2].
- In mice fed a high-fat diet for 16 weeks, oral TUDCA over the final 4 weeks reduced intestinal inflammation and barrier disruption alongside less liver fat[3].
- No human trial has measured intestinal permeability on TUDCA. The piglet dose was 200 mg/kg of feed and the cell work used 100 micromolar, and neither converts into a capsule dose.
The Barrier, and Why a Bile Acid Would Touch It
Intestinal epithelial cells are replaced every few days and sealed to each other by tight junction proteins. Two things break that seal: the cells dying faster than they are replaced, and the junctions themselves loosening. Both are downstream of the same stresses, and both are things an ER stress inhibitor might plausibly influence.
There is also a direct receptor story. TGR5, also called GPBAR1, is a cell surface receptor for bile acids and it is expressed on intestinal epithelium. TUDCA is a bile acid. So unlike most of the compounds sold for gut health, there is an obvious reason it would have a specific, targeted effect on these cells rather than a vague one.
That matters for reading this literature, because a mechanism that can be switched off is a mechanism that can be tested. Several of the studies below do exactly that.
The Piglet Study Is the Most Useful One
A 2022 paper in Journal of Animal Science and Biotechnology is the closest thing here to a real-world feeding trial[1]. Seventy-two healthy weaned piglets were split into two groups matched on sex and body weight, and fed either the basal diet or the basal diet with 200 mg/kg TUDCA for 30 days. Weaning is a natural gut barrier insult in pigs, which is why the model exists.
Dietary TUDCA significantly reduced diarrhoea incidence, which is an outcome rather than a biomarker, and the authors attributed it to improved barrier function and immunity. Serum metabolites and the relative abundance of several gut bacteria also shifted.
The mechanistic half is the part worth respecting. In porcine intestinal epithelial cells given 100 micromolar TUDCA, barrier damage caused by E. coli was reduced and TGR5 protein rose. Then they knocked down TGR5, and separately inhibited myosin light chain kinase, and in both cases the protection disappeared. That is a causal test, not an association.
One limitation is easy to miss in the abstract. Although 72 animals were fed, only three females and three males per group, chosen as representative of average body weight, were slaughtered for tissue sampling. The diarrhoea outcome rests on the full group; the tissue and molecular measurements rest on six animals per group.
Colitis Models Show the Barrier Effect Most Clearly
A 2014 study in Laboratory Investigation used dextran sulfate sodium to produce ulcerative colitis-like barrier failure in mice[2]. The headline number is stark: mice given vehicle showed a cumulative mortality of 40 percent, and all TUDCA-treated mice survived the 14-day follow-up.
More informative than the survival figure is the sequence the authors reconstructed. The earliest event they could tie to clinical benefit was prevention of caspase-3 induction in the colon, a marker of epithelial cell death that is also over-activated in human ulcerative colitis. Consistent with a barrier that held, TUDCA reduced bacterial translocation to the spleen and stimulated mucin production, and it blocked the rise in intestinal permeability and enterocyte apoptosis caused by lipopolysaccharide. In human HT29 colonic cells the anti-apoptotic effect was dose dependent and worked against both receptor-dependent and receptor-independent triggers.
A 2024 paper in Journal of Pharmacology and Experimental Therapeutics repeated the general finding in 3 percent DSS colitis, reporting improvements in disease activity index, colon length and spleen weight ratio alongside changes in tight junction proteins and the microbiome[4]. And in a quite different setting, TUDCA inhibited apoptosis caused by Clostridioides difficile toxins in intestinal cells[5], which is the same protective mechanism arriving from a bacterial toxin rather than a chemical irritant.
The authors of the 2014 study drew the conservative conclusion: TUDCA might work as an add-on to existing immunosuppressive treatment of ulcerative colitis. Add-on, and might. That is the appropriate register for animal data, and it is worth noting that in the twelve years since, no human trial has tested it.
The Gut and Liver Arm of the Same Story
A 2018 paper in British Journal of Pharmacology is the one most relevant to why people on this site already take TUDCA[3]. Mice were fed a high-fat diet for 16 weeks to produce fatty liver disease, then given oral TUDCA during the final 4 weeks. It attenuated liver fat and inflammation, and on the intestinal side it reduced inflammation and barrier disruption, with changes in tight junction gene expression and microbiota composition.
This is the gut-liver axis argument in its cleanest experimental form. Bacterial products crossing a loosened intestinal barrier reach the liver first, so a leaky gut is a plausible contributor to liver inflammation, and a compound that tightens the barrier has a route to helping the liver that has nothing to do with acting on hepatocytes. It is a reasonable mechanism and it sits alongside, not instead of, the direct hepatic effects covered on the NASH and fatty liver page.
It is still a mouse on a 16-week high-fat diet, with TUDCA started at week 12 of a designed insult.
What This Does and Does Not Support
It supports the claim that TUDCA can tighten a damaged intestinal barrier in animals, that the effect runs at least partly through TGR5, and that it is protective across several unrelated insults, which is the kind of consistency that makes a mechanism believable.
It does not support taking TUDCA to fix leaky gut, for two reasons that have nothing to do with study quality. The first is dose. The piglet study fed 200 mg/kg of diet for 30 days and the cell experiments used 100 micromolar in a well; neither translates to a human capsule, and the dosing page is explicit that human dose ranges come from liver studies, not gut ones. The second is that every one of these models starts by deliberately damaging a healthy gut. Whether TUDCA does anything measurable to an intact barrier in a person with vague digestive symptoms is not a question any of this work asked.
If you already have a diagnosed inflammatory bowel disease, the specific page for that is here, and the relevant point is that the researchers themselves framed TUDCA as a possible addition to treatment rather than a replacement for it. Check interactions before adding anything to an immunosuppressive regimen.
Nothing on this page is medical advice. Persistent digestive symptoms deserve a diagnosis rather than a supplement, because several of the conditions that loosen the gut barrier are treatable and some are serious.
Frequently Asked Questions
Does TUDCA help leaky gut?
In animals, TUDCA tightened a damaged intestinal barrier, reduced bacterial translocation and increased mucin production[2], and improved barrier function in piglets fed 200 mg/kg for 30 days[1]. No human study has measured intestinal permeability on TUDCA, and leaky gut is not a clinical diagnosis. The animal evidence is genuinely good and it is not evidence about people.
How would a bile acid tighten tight junctions?
Through TGR5, a cell surface bile acid receptor expressed on intestinal epithelium. In porcine intestinal cells, TUDCA raised TGR5 protein and protected the barrier against E. coli, and knocking down TGR5 or inhibiting myosin light chain kinase abolished that protection[1]. TUDCA also reduces epithelial cell death, with prevention of colonic caspase-3 activation the earliest measurable event in a mouse colitis model[2].
Is the gut barrier effect why TUDCA helps the liver?
It may be part of it. In high-fat-diet mice, oral TUDCA reduced intestinal inflammation and barrier disruption at the same time as liver fat and inflammation[3], which is the gut-liver axis mechanism: fewer bacterial products crossing the gut wall means less inflammatory load reaching the liver. It is a plausible additional route rather than a replacement for TUDCA’s direct effects on liver cells.
Can TUDCA replace treatment for colitis?
No, and the researchers did not suggest it could. The 2014 mouse study concluded TUDCA could be an add-on strategy to current immunosuppressive treatment of ulcerative colitis[2], and no human trial has tested even that. Stopping or reducing an immunosuppressant is a decision for the prescribing clinician.
References
- Tauroursodeoxycholic acid (TUDCA) improves intestinal barrier function associated with TGR5-MLCK pathway and the alteration of serum metabolites and gut bacteria in weaned piglets. J Anim Sci Biotechnol (2022).
- Tauroursodeoxycholic acid inhibits experimental colitis by preventing early intestinal epithelial cell death. Lab Invest (2014).
- Tauroursodeoxycholic acid inhibits intestinal inflammation and barrier disruption in mice with non-alcoholic fatty liver disease. Br J Pharmacol (2018).
- Tauroursodeoxycholic Acid Reverses Dextran Sulfate Sodium-Induced Colitis in Mice via Modulation of Intestinal Barrier Dysfunction and Microbiome Dysregulation. J Pharmacol Exp Ther (2024).
- Tauroursodeoxycholic Acid Inhibits Clostridioides difficile Toxin-Induced Apoptosis. Infect Immun (2022).
These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure, or prevent any disease. Content is for informational purposes only and is not medical advice; consult a qualified healthcare provider before starting any supplement. As an Amazon Associate we earn from qualifying purchases.
